



FOCUS

Future of Care in Understanding Steatohepatitis


MASLD




Sonesta Hotel
Track location



16&17 | JULY | 2026
Add to your calendar



Registration
Tab to register



Organized by



EVA PHARMA



FOCUS - Middle East School of Steatotic Liver Disease (SLD)



We are pleased to invite you to participate in the **Middle East School of Steatotic Liver Disease**, a dedicated educational initiative focused on **MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)** and fatty liver disease.



Program Overview

This scientific program is designed to support hepatogastroenterologists across the Middle East, with the aim of addressing the increasing burden of liver diseases.

In **2026**, the curriculum will feature a comprehensive SLD module that integrates the latest global research, evolving disease nomenclature, and current best practices in diagnosis, management, and prevention.



Program Format

The training will be delivered across three structured waves, ensuring progressive learning and continuous engagement:

- 1 Module 1:** Pathophysiology, Epidemiology & Diagnosis Foundations
- 2 Module 2:** MASLD Risk Assessment & Therapeutic Interventions
- 3 Module 3:** MASLD Cirrhosis, Multidisciplinary Care & Public Health Integration



Key Benefits for Participants

- Stay updated on the most common chronic liver disease worldwide (**MASLD**) whose prevalence continues to rise
- Gain hands-on knowledge to enhance your clinical practice
- Network with peers and regional & International experts in hepatology

16&17 | **JULY** | 2026

Organized by



EVA PHARMA

FOCUS

Future of Care in Understanding Steatohepatitis MASLD

COMMITTEE

UCHID ADVISORY BOARD



Gamal Esmat



Imam Waked



Maysaa Abdallah

COURSE CO-ORDINATORS



Ahmed Cordie



Faisal Abalkhail



Fatma Elrashdy



Sven Francque

ORGANIZING TEAM



Haneen Mohamed Ahmed



Ibrahim Amer



Mahmoud Hesham



Mohamed Abdallah



Sara Khaled



Youssef Khaled



FOCUS

Future of Care in Understanding Steatohepatitis MASLD

COMMITTEE

INTERNATIONAL SPEAKERS



Andreea Ciudin



Fayez Zannad



Hugo López



Kate Hallsworth



Luca Miele



Maria Reig



Raluca Pais



Sven Francque



Wilhelmus Kwanten

16&17 | **JULY** | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD

COMMITTEE

NATIONAL FACULTY



Ahmed Tageldien



Alaa Noah



Amal Mohamed Youssef



Ashraf El Bereedy



Dina Hazem Ziada



Hossam Abdel Aziz



Khaled Safwat



Maher Fawzy



Mai Magdy



Marwa Othman



Merna Marwan



Mohamed Amin Sakr



Mohamed Hassan Fahmy



Mohamed Hassany



Mohsen Salama



Mona Amin



Noha Gaber



Noha Sabry



Sahar Zaghloul



Shadwa Ahmed



Yasmine Gaber



Zeinab Hefny

16&17 JULY 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD

COMMITTEE

MENTORS & PANELISTS



Alaa Mohamed



Doaa Abdeltawab



Marwa Khalaf



Noura Gamal



Rania Elkafoury



Reham Reda



Sara Hassan



Shima Kilany Almahdy



Wael Soliman

16&17 | **JULY** | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD

DAY
1

Time	Lecture	Speakers	Chairpersons
02:00 PM - 03:00 PM	Lunch		
03:00 PM - 03:20 PM	Why to treat MASLD-MASH? What are the goals?	Sven Francque	
03:20 PM - 03:40 PM	HCC in non-cirrhotic MASLD and in CLD of mixed aetiology: how big is the problem	Maria Reig	Ahmed Tageldien
03:40 PM - 03:50 PM	Discussion		Ashraf El Bereedy
03:50 PM - 04:20 PM	Case discussion: Screening for HCC in SLD patients	Ahmed Cordie Ibrahim Amer	Dina Hazem Ziada
04:20 PM - 04:30 PM	Discussion		Maher Fawzy
04:30 PM - 04:50 PM	Assessment of disease severity in the CKLM framework Assessment of associated cardio-renal-metabolic risk actors and disease severity	Fayez Zannad	Mohamed Abdallah
04:50 PM - 05:10 PM	What is different the Egyptian context	Ahmed Tageldien	
05:10 PM - 05:30 PM	Obesity introduction and relation to MASLD	Andreea Ciudin	
05:30 PM - 06:00 PM	Coffee Break		

16&17 | JULY | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD

DAY
1

Time	Lecture	Speakers	Chairpersons
06:00 PM - 06:30 PM	SLD patients' stratification	Sven Francque	Amal Mohamed Youssef
06:30 PM - 07:00 PM	Dietary Management of SLD patients	Zeinab Hefny	Mai Magdy
07:00 PM - 07:30 PM	Physical activity in SLD patients	Kate Hallsworth	Mohamed Amin Sakr
07:30 PM - 08:00 PM	Patient cantered approach: from motivation to intervention	Noha Sabry	Sahar Zaghloul
08:00 PM - 09:00 PM	Dinner (Meet the Mentors)		

16&17 | JULY | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD



SVEN FRANCQUE

Prof. Sven Francque is a leading expert in gastroenterology and hepatology, with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) and portal hypertension as key expertise. He earned his MD from the University of Antwerp and completed training in Belgium and France.

Prof. Francque received his PhD in 2011, focusing on vascular changes in steatosis.

He has authored over 300 papers and book chapters and served as an editor for JHep Reports. Currently, he is the chairman of the Department of Gastroenterology and Hepatology at the University Hospital Antwerp and a senior full professor at the University of Antwerp.

He is also a key figure in Belgian gastroenterology, coordinating national MASLD guidelines and the Belgian Week of Gastroenterology.

He is member of the EASL Governing Board as educational councilor.

16&17 | **JULY** | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD

Dr. Maria Reig, MD, PhD, is an internationally recognized physician-scientist specializing in liver diseases and hepatocellular carcinoma (HCC).

She serves as Head of the Hepatic Oncology Unit at Hospital Clínic Barcelona, the Barcelona Clinic Liver Cancer (BCLC) group at IDIBAPS, and the Hepatic Oncology Group at CIBEREHD, while also sitting on the CIBEREHD Steering Committee. She has 172 peer-reviewed articles, earning over 20,700 citations (h-index of 51). Supported by competitive grants and global collaborations in translational oncology, immunotherapy, and precision medicine, she has heavily influenced the BCLC strategy, developing innovative decision-making concepts like CUSE and leading its 2026 update.

Globally, Dr. Reig chairs the International Working Group of the Liver Cancer Council at the Global Liver Institute and has served on the boards of ILCA, AEEH, ERN-rareLiver, and EASL. Notably, she is the first woman to chair the EASL Scientific Committee and to lead HCC management guidelines in Spain and Europe.



MARIA REIG

16&17 | JULY | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD



Fayez Zannad, MD, cardiologist,
PhD in clinical pharmacology,

Professor Emeritus of Therapeutics at the University of Lorraine.

He directed the Inserm Clinical Investigation Center (CIC) in Nancy for 30 years. Former president of the French Society of Hypertension.

A specialist in heart failure and clinical trials, he contributed to the development of most of the clinical evidence for drug treatments for heart failure. Recipient of several EU research grants. Founder of a global, multi-stakeholder think tank, in partnership with the US FDA, on cardiovascular clinical trials (CVCT), dedicated to the science of clinical trials. Recipient of the Clarivate Award for Highly Cited Researcher. Eugene Braunwald Scholar – Harvard Medical School.

16&17 | JULY | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD



ANDREEA CIUDIN

Dr. Andreea Ciudin, female,
born in 1979, PhD,

is a specialist in Endocrinology and Nutrition at the Hospital Vall d'Hebron, Barcelona, Spain and Associated Professor of Human Physiology at Facultat de Medicina of Universitat Autònoma de Barcelona, focusing the clinical activity in obesity and its complications.

Dr. Ciudin coordinates the Obesity Unit of the Vall Hebron University Hospital, since 2013 which is EASO- COM. She is the treasurer of the Spanish Society for the Study of Obesity (SEEDO), member of the executive board and co-chair of the Obesity Management Working Group of the European Association for the Study of Obesity (EASO). Dr. Ciudin is a senior researcher of the Diabetes and Metabolism Research Group (Vall Hebron Institut de Recerca-VHIR) as PI in the investigational line in Obesity and its complications, mainly focused on MAFLD, cognitive impairment, sarcopenic obesity and medical complications of bariatric surgery.

16&17 | **JULY** | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD

Dr. Kate Hallsworth is a Consultant Allied Health Professional (AHP)/Clinical Academic Physiotherapist and NIHR Senior Clinical and Practitioner Research

Awardee (SCPRA) within the Liver Unit at Newcastle upon Tyne Hospitals NHS Foundation Trust (NuTH), UK. Following her Newcastle University PhD on 'Physical activity and exercise in MASLD,' she published research on lifestyle management for long-term conditions and identified barriers to optimizing clinical lifestyle interventions, prompting her to develop an evidence-based, patient-co-designed MASLD-specific digital intervention piloted within the Newcastle NHS.

Clinically, she leads an innovative, AHP-led structured group education programme for MASLD patients within one of the UK's largest MASLD services. She co-led an Active Hospitals Pilot embedding physical activity into NuTH care pathways and leads initiatives helping patients with long-term conditions self-manage via non-pharmacological interventions. Globally, she serves on the EASL Nurse and AHP Taskforce and BASL AHP Committee. Her expertise contributed to international groups authoring EASL MASLD Patient Guidelines, plus ACSM and ESSA position statements on physical activity and exercise in MASLD. In 2021, she received the prestigious EASL Rising Star Award for putting people with or at risk of liver disease at the heart of her practice.



KATE HALLSWORTH

16&17 | JULY | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD

DAY
2

Time	Lecture	Speakers	Chairpersons
09:30 AM - 10:00 AM	Recap by Mentors		
10:00 AM - 10:20 AM	Lifestyle modifications other than diet and exercise	Luca Miele	Hossam Abdel Aziz Ibrahim Amer Maysaa Abdallah Mohsen Salama Sven Franque
10:20 AM - 10:40 AM	Motivational Interviewing for lifestyle interventions	Hugo López	
10:40 AM - 11:00 AM	GLP1RA, dual and triple agonist	Noha Gaber	
11:00 AM - 11:10 AM	Discussion		
11:10 AM - 11:30 AM	Other anti-diabetes medications	Mona Amin	
11:30 AM - 11:50 AM	Other medications to be used in SLD patient	Wilhelmus Kwanten	
11:50 AM - 12:00 PM	Discussion		
12:00 PM - 12:30 PM	Resmetirom and other thyroid hormone receptor agonists for SLD	Raluca Pais	
12:30 PM - 02:00 PM	Coffee Break & Prayer		

16&17 | JULY | 2026



FOCUS

Future of Care in Understanding Steatohepatitis MASLD

DAY
2

Time	Lecture	Speakers	Chairpersons
02:00 PM - 05:00 PM	General ultrasound hands-on training	Yasmine Gaber	
02:00 PM - 05:00 PM	How to prepare a dietary plan and exercise prescription for your MASLD patient	Marwa Othman Merna Marwan Shadwa Ahmed	Alaa Noah
02:00 PM - 05:00 PM	Case scenarios discussion with expert	Fatma Elrashdy Sven Francque	Khaled Safwat Mohamed Hassany
05:00 PM - 05:30 PM	Possible future treatments	Luca Miele	Sven Francque
05:30 PM - 05:50 PM	Role of bariatric surgery in SLD patients	Mohamed Hassan Fahmy	
05:50 PM - 06:10 PM	Keynote lecture: Translating WHA SLD resolution into national Priorities	Mohamed Hassany	
06:10 PM - 06:30 PM	Keynote lecture: Microbiota and MASLD	Gamal Esmat	
06:30 PM - 07:00 PM	Dinner		

16&17 | JULY | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD

Prof. Dr. Luca Miele is Associate Professor of Internal Medicine at Università Cattolica del Sacro Cuore (UCSC), Rome, and Director of the Liver Pre-Transplant Clinical Unit at Fondazione Policlinico Universitario A. Gemelli IRCCS.



Holding the Italian National Scientific Qualification for Full Professor in Internal Medicine, he trained in hepatology in Italy and the UK (Liver Research Group, University of Newcastle upon Tyne).

His research on MASLD/MASH, liver fibrosis, and hepatocellular carcinoma integrates translational hepatology, multi-omics, biomarker discovery, clinical epidemiology, and AI precision medicine.

He coordinates UCSC/Gemelli units within European consortia LITMUS and GRIPonMASH and is a member of the European NAFLD Registry and Global NASH Council.

A Stanford University World's Top 2% Scientist, Dr. Miele has authored 280+ peer-reviewed publications (Scopus h-index 62). He is a phase II–IV clinical trial principal investigator and reviewer for funding bodies including Horizon Europe, the Wellcome Trust, and the Swiss National Science Foundation. He also sits on several journal editorial boards and holds leadership roles within UEG, AISF, and SIGE.

16&17 | JULY | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD



HUGO LÓPEZ

Hugo López-Pelayo is medical doctor (Universitat Rovira i Virgili, 2008), specialist in psychiatry by Hospital Clínic de Barcelona (2013),

with PhD in translational medicine (2018) by University of Barcelona.

Currently, he works in Addictions Unit and Consultation-Liaison Psychiatry Section of Hospital Clínic de Barcelona.

He is the Interim Junior Group Leader of Addictions Research Group of Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS).

His research is focused in digital health for drug and alcohol use disorders, management of the alcohol use disorder in complex patients, and early identification and intervention of cannabis use and cannabis use disorders.

He is the vice-president of the Spanish Society of Drug and Drug Addictions Socidrogalcohol. He is author of more than 90 scientific papers.

He attended to TNT in Motivational Interviewing in 2015 (Berlin), and he is trainer on motivational interviewing and brief interventions.

16&17 | **JULY** | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD

Wilhelmus (better known as Wilco) Kwanten is a research physician affiliated to the Antwerp University Hospital and University of Antwerp in Belgium.



WILHELMUS KWANTEN

He was trained at the same university in Antwerp (BE) and did postdoctoral research at the Massachusetts General Hospital in Boston (USA).

Dr Kwanten is active in the field of hepatology. His main interest, both in clinic as in research, is non-alcoholic fatty liver disease (NAFLD). Amongst others, intra- and extrahepatic vascular alterations are associated with NAFLD and also believed to be an important driver of disease progression. His research focusses on the intrahepatic (micro)vascular dysfunction that can already be observed early in the disease course of NAFLD.

In mouse models disease course can be modified by targeting the vascular dysfunction.

16&17 | **JULY** | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD



RALUCA PAIS

Dr. Raluca Pais is an internationally recognized hepatologist and clinical researcher specializing in MASLD/MASH across the translational, clinical, and market innovation cycle.

Based at Pitié-Salpêtrière Hospital (Paris) since 2009 and holding a Sorbonne University PhD, Dr. Pais works at the intersection of hepatology, metabolic disease, the clinical trial design, and the precision medicine, collaborating within the IHU ICAN on metabolic disorders and systemic complications.

Integrating precision hepatology with translational science, Dr. Pais founded France's first structured clinical hub for metabolic steatosis: the multidisciplinary MASH Clinic at Pitié-Salpêtrière Hospital. This platform intercepts complications like atherosclerosis, hypertension, and diabetes, tailoring therapies to patients' clinical phenotypes, personal histories, and environmental contexts.

Dr. Pais contributes to EU-funded consortia GRIPONMASH, LiverAIM, LITMUS/EDC MASLD, and ARTEMIS, partnering with academia, industry, regulators, and patient organizations to accelerate biomarker validation and therapeutic innovation.

Globally, she is an EASL international speaker and reviewer for The Lancet Gastroenterology & Hepatology, Journal of Hepatology, Hepatology, and Alimentary Pharmacology & Therapeutics.

16&17 | **JULY** | 2026

Organized by



**Mentor**
**GROUP
1**
Rania Elkafoury

Tanta University Hospitals

Name**University / Hospital**

Alaa Hafez

Alexandria University

Aya AwadElkarim

Aswan University Hospital

Hanan Hamdy

Cairo University Hospitals

Mohamed Magdy

Ain Shams University

Omar Ashraf

Kafr-Elsheikh University Hospital

Tasnim Farouk

Tanta University

Mentor
**GROUP
2**
Alaa M. Mostafa

Minia University. Hepatology Center

Name**University / Hospital**

Amena Salem

Suez Canal University Teaching Hospitals

Bavly Ashraf

Cairo University

Esraa Ibrahim

Alexandria University

Hazem Ahmed

Ain Shams University

Mostafa Mahmoud

Kafr-Elsheikh University

Nourhan Salah

Fayoum University

Mentor
**GROUP
3**
Marwa Khalaf

Assuit Liver Center

Name**University / Hospital**

Amr Rajeh Hussein

Minya University Hospital

Fatma Mahmoud

Alexandria University

Mahmoud Ahmed

Cairo University

Marwan Ahmed

Fayoum General Hospital

Rawnaa AbdelAziz

Tanta University

16&17 | **JULY** | 2026

Organized by



EVA PHARMA

**Mentor**

GROUP
4

Noura Gamal

Tanta University Hospitals

Name**University / Hospital**

Mohamed Ahmed

Cairo University

Mohamed Nabil

Kafr-Elsheikh University

Mohammed Bakr

Mansoura University

Rana Tarek

Fayoum University

Reem Elsharkawy

Cairo University

Mentor

GROUP
5

Sara Hassan

Ain Shams University

Name**University / Hospital**

Amira Shaaban

Tanta University

Gomaa Desouky

Fever Hospital Fayoum

Mohamed Sobhy

Cairo University

Said Adel

Beni Suef University

Sara Sayed

Suez Canal University

Mentor

GROUP
6

Reham Reda

National Liver Institute Menoufia University

Name**University / Hospital**

Lina Saed

Damanhour Hospital

Safaa Soliman

Ain Shams University

Shaimaa Magdy

Ras El Tin General Hospital

Sherief Sholkamy

Beni Suef University

Youssra Mohamed

Suez Canal University

16&17 | **JULY** | 2026

Organized by



EVA PHARMA